444289

Marimastat

An orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor that targets both the substrate binding site and the active-site Zn²⁺.

• Sinónimos: Marimastat, (2S,3R)-N⁴-((1S)-2,2-Dimethyl-1-((methylamino)carbonyl)propyl)-N¹,2-hydroxy-3-(2-methylpropyl)butanediamide, BB-2516
• Fórmula empírica (notación de Hill): C₁₅H₂₉N₃O₅
• Número de CAS: 154039-60-8
• Peso molecular: 331.41
• MDL number: MFCD00866242
• UNSPSC Code: 12352200

Propiedades

• Quality Level: 100
• assay: ≥98% (NMR)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; protect from light
• color: white
• solubility: DMSO: 15 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C
• InChI: 1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
• InChI key: OCSMOTCMPXTDND-OUAUKWLOSA-N

Descripción

General description

An orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC₅₀ in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn²⁺. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Hansen, H.P., et al. 2002. Int. J. Cancer98, 210.
Tsuji, F., et al. 2002. Cytokine17, 294.
Barlaam, B., et al. 1999. J. Med. Chem.42, 4890.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther.75, 69.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable